Genomics

Dataset Information

0

MiR-33b-3p Suppresses Metastasis in Prostate Cancer by Targeting DOCK4


ABSTRACT: Purpose: Despite that androgen-deprivation therapy results in long-lasting responses, the disease inevitably progresses to metastatic castration-resistant prostate cancer. In this study, we identified miR-33b-3p as a suppressor of metastasis in prostate cancer. miR-33b-3p was significantly reduced in prostate cancer tissues, and the low expression of miR-33b-3p was correlated with poor overall survival of prostate cancer patients. Overexpression of miR-33b-3p inhibited both migration and invasion of highly metastatic prostate cancer cells whereas antagonizing miR-33b-3p promoted those processes in lowly metastatic cells. The in vivo results demonstrate that miR-33b-3p suppresses metastasis of tail vein inoculated prostate cancer cells to lung, liver, and lymph node in mice. DOCK4 was validated as the direct target of miR-33b-3p. miR-33b-3p decreased the expression of DOCK4 and restoration of DOCK4 could rescue miR-33b-3p inhibition on cell migration and invasion. Moreover, downregulation of miR-33b-3p was induced by bortezomib, the clinically used proteasome inhibitor, and overexpression of miR-33b-3p rescued the insufficient inhibition of bortezomib on migration and invasion in prostate cancer cells. Collectively, our findings demonstrate that miR-33b-3p suppresses metastasis by targeting DOCK4 in prostate cancer. Our results suggest that enhancing miR-33b-3p expression may provide a promising therapeutic strategy for overcoming that proteasome inhibitor’s poor efficacy against metastatic prostate cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE183428 | GEO | 2021/09/08

REPOSITORIES: GEO

Similar Datasets

2022-06-15 | GSE179399 | GEO
| PRJNA760771 | ENA
2022-02-17 | PXD026901 | Pride
2022-01-01 | GSE166799 | GEO
2020-05-09 | GSE150143 | GEO
2020-05-09 | GSE150142 | GEO
2023-03-10 | GSE224301 | GEO
2021-02-24 | GSE161419 | GEO
| E-GEOD-49342 | biostudies-arrayexpress
2017-04-25 | GSE57077 | GEO